The 340B Drug Discount Program has faced numerous attempts at regulatory changes in the last five years; one, in particular, challenged the Orphan Drug rule. The ruling stipulated that manufacturers are not required to provide covered entities orphan drugs under 340B, but a manufacturer may, at...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
After President Trump entered office, the administration repeatedly delayed the implementation of a 340B rule that was finalized at the end of the Obama administration. Recently, the Trump administration has indicated that they plan to not only implement the rule but also accelerate...
Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Cancer (ASC) payment system are supported by the Centers for Medicare & Medicaid Services (CMS) for 2019. The...
In June, the Director of HRSA’s Office of Pharmacy Affairs, Captain Krista Pedley, testified before the U.S. Senate Committee On Health, Education, Labor, and Pensions. In her testimony, she stated, “Specific legislative authority to conduct rulemaking for all provisions in the 340B statute would be...
Despite multiple delays, the Secretary of Health and Human Services, Alex Azar, recently renewed his agencies plan to release regulations for setting 340B drug discount program drug prices. While speaking to the hospital trade group, 340B Health, Azar addressed the provider’s concerns that the multiple delays...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
Prescription drug prices continue to rise and have become one the most important healthcare issues facing the nation. In an effort to address the problem, President Trump announced his drug pricing plan on May 11. After his remarks, analysts are concerned that it could significantly...
In 2015, the 340B Drug Discount Program saved healthcare providers $6 billion on drug acquisition costs. While the program aims to make pharmaceutical and clinical care affordable and accessible to low-income patients; there is evidence that some participating entities are exploiting its discounts for profit. Since close...
The 340B drug discount program helps disproportionate share hospitals (DSHs) to serve low-income patients. The stated objective of the 340B drug discount program is to “stretch federal resources as far as possible reaching more eligible patients and providing more comprehensive services.” Over time the program...